XML 40 R24.htm IDEA: XBRL DOCUMENT v3.3.1.900
Segment Information
12 Months Ended
Dec. 31, 2015
Segment Information  
Segment Information

17. Segment Information

        We currently operate as one operating segment. However, our chief operating decision makers regularly review net product sales, cost of product sales and gross profit data as a primary measure of performance for each of our five commercial products. We commenced sales of Orenitram and Unituxin during the second quarter of 2014 and third quarter of 2015, respectively.

        Net product sales, cost of product sales and gross profit for each of our commercial products were as follows (in thousands):

                                                                                                                                                                                    

Year Ended December 31, 2015

 

Remodulin

 

Tyvaso

 

Adcirca

 

Orenitram

 

Unituxin

 

Total

 

Net product sales

 

$

572,795 

 

$

470,069 

 

$

278,829 

 

$

118,434 

 

$

20,443 

 

$

1,460,570 

 

Cost of product sales

 

 

12,373 

 

 

23,925 

 

 

16,504 

 

 

12,569 

 

 

3,665 

 

 

69,036 

 

​  

​  

​  

​  

​  

​  

​  

​  

​  

​  

​  

​  

Gross profit

 

$

560,422 

 

$

446,144 

 

$

262,325 

 

$

105,865 

 

$

16,778 

 

$

1,391,534 

 

​  

​  

​  

​  

​  

​  

​  

​  

​  

​  

​  

​  

​  

​  

​  

​  

​  

​  

​  

​  

​  

​  

​  

​  

Year Ended December 31, 2014

 

 


 

 

 


 

 

 


 

 

 


 

 

 


 

 

 


 

 

Net product sales

 


$

553,728 

 


$

463,067 

 


$

221,471 

 


$

41,267 

 


$


 


$

1,279,533 

 

Cost of product sales

 

 

47,327 

 

 

57,442 

 

 

13,495 

 

 

7,619 

 

 

 

 

125,883 

 

​  

​  

​  

​  

​  

​  

​  

​  

​  

​  

​  

​  

Gross profit

 

$

506,401 

 

$

405,625 

 

$

207,976 

 

$

33,648 

 

$

 

$

1,153,650 

 

​  

​  

​  

​  

​  

​  

​  

​  

​  

​  

​  

​  

​  

​  

​  

​  

​  

​  

​  

​  

​  

​  

​  

​  

Year Ended December 31, 2013

 

 


 

 

 


 

 

 


 

 

 


 

 

 


 

 

 


 

 

Net product sales

 


$

491,179 

 


$

438,793 

 


$

176,972 

 


$


 


$


 


$

1,106,944 

 

Cost of product sales

 

 

59,314 

 

 

60,831 

 

 

10,982 

 

 

 

 

 

 

131,127 

 

​  

​  

​  

​  

​  

​  

​  

​  

​  

​  

​  

​  

Gross profit

 

$

431,865 

 

$

377,962 

 

$

165,990 

 

$

 

$

 

$

975,817 

 

​  

​  

​  

​  

​  

​  

​  

​  

​  

​  

​  

​  

​  

​  

​  

​  

​  

​  

​  

​  

​  

​  

​  

​  

        Geographic revenues are determined based on the country in which our customers (distributors) are located. Total revenues from external customers by geographic area are as follows (in thousands):

                                                                                                                                                                                    

Year Ended December 31,

 

2015

 

2014

 

2013

 

United States

 

$

1,353,002 

 

$

1,180,759 

 

$

1,032,435 

 

Rest-of-World(1)

 

 

112,759 

 

 

107,760 

 

 

84,549 

 

​  

​  

​  

​  

​  

​  

Total(2)

 

$

1,465,761 

 

$

1,288,519 

 

$

1,116,984 

 

​  

​  

​  

​  

​  

​  

​  

​  

​  

​  

​  

​  


 

 

 

(1)          

Primarily Europe.

(2)          

Total includes other revenue of $5.2 million, $9.0 million and $10.0 million for the years ended December 31, 2015, 2014 and 2013, respectively.

        For the years ended December 31, 2015, 2014 and 2013, net product sales to Accredo Health Group, Inc. comprised 55 percent, 58 percent and 57 percent, respectively of total revenues.

        Long-lived assets (property, plant and equipment) located by geographic area are as follows (in thousands):

                                                                                                                                                                                    

Year Ended December 31,

 

2015

 

2014

 

United States

 

$

481,219 

 

$

462,377 

 

Rest-of-World(1)

 

 

14,555 

 

 

16,044 

 

​  

​  

​  

​  

Total

 

$

495,774 

 

$

478,421 

 

​  

​  

​  

​  

​  

​  

​  

​  


 

 

 

(1)          

Facilities principally located in the United Kingdom.